We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Informatics

Informatics

Stay up to date on the topics that matter to you

A picture of Laura Elizabeth Lansdowne

Laura Elizabeth Lansdowne profile page

Managing Editor

at Technology Networks

As managing editor, Laura works with the editorial director to create, inform and maintain the overall editorial strategy for Technology Networks. She oversees the in-house editorial team and works directly with commissioned writers to produce content across the publication’s communities. After obtaining a first-class honors degree in biology, Laura worked as a quality assurance technologist before joining the Wellcome Sanger Institute and undertaking an additional qualification in clinical chemistry. In 2015, she left to pursue pharmaceutical and editorial-based roles, before joining Technology Networks in 2017.

Education

University of Kent

Nottingham Trent University

Writtle University College

Chartered Institute of Editing and Proofreading

Accreditations

Biology, BSc (Hons) recognised by The University of Kent

Areas of Expertise

Drug Screening Strategies

Pharmaceutical Development

Molecular & Cellular Biology

Got a Question for Laura Elizabeth Lansdowne?

Get in touch using the contact form linked here and we’ll get back to you shortly

Published Content

Total: 409

Large-Scale Bioproduction of Adherent Cells To Support Advanced Therapy Workflows content piece image

Industry Insight

Large-Scale Bioproduction of Adherent Cells To Support Advanced Therapy Workflows

In recent years, a number of new cell and gene therapies have been developed to treat a variety of indications, including cancer and inherited retinal dystrophies. While these therapies have proven to be beneficial to patients, their scalability and manufacturability are two enduring challenges. Technology Networks spoke to Tara St.Amand, PhD, MBA, director of business technology, bioprocess at Corning to learn more about the key challenges faced when scaling up the manufacturing of cell products.

Spatial Biology content piece image

Spatial Biology

Download this infographic to discover how spatial biology can elucidate biological activity in relation to environment, is utilized in neuroscience and cancer research, and can be explored using various technologies.

Simulator Technology Can Predict Optimal Vaccine Dosing content piece image

Industry Insight

Simulator Technology Can Predict Optimal Vaccine Dosing

Certara is developing biosimulation and tech-enabled approaches to help scientists answer key questions at various stages of the development pipeline, serving to inform and accelerate the path to regulatory approval. One such approach, the company’s Vaccine Simulator™, can be leveraged across different therapeutic areas to determine optimal vaccine dosing and dosing regimens for different patient cohorts.

Treating Hearing Loss: The Hunt for Drugs That Promote Hair Cell Regeneration content piece image

Treating Hearing Loss: The Hunt for Drugs That Promote Hair Cell Regeneration

A research team from Nanjing University has used cochlear organoids to identify drugs that can promote the regeneration of hair cells. The study, published in Stem Cell Reports, also identifies a signaling pathway as a potential target for hearing restoration.

High-Intensity Focused Ultrasound: A Novel Non-Invasive Cancer Treatment content piece image

High-Intensity Focused Ultrasound: A Novel Non-Invasive Cancer Treatment

A research team has examined the use of high-intensity focused ultrasound as a non-invasive cancer treatment that works by targeting acoustic waves to destroy cancer cells. The study was published in Bulletin of Mathematical Biology.

Opinionated Science Episode 34: Genetics of Endometriosis, the Birthing Brain and Cancer Vaccines content piece image

Opinionated Science Episode 34: Genetics of Endometriosis, the Birthing Brain and Cancer Vaccines

In this episode, the Technology Networks team reviews world-leading research into the mechanisms behind endometriosis, a condition that affects up to 10% of women of reproductive age, but often takes a decade to diagnose. There's also a peek into mom's brain during birth and a new cancer vaccine that harnesses similar technology used to create the Oxford–AstraZeneva COVID-19 vaccine.

Nine Existing Drugs Reduce SARS-CoV-2 Viral Load in Cell-Based Study content piece image

Nine Existing Drugs Reduce SARS-CoV-2 Viral Load in Cell-Based Study

A new study by researchers at the University of Manchester suggests that existing FDA-approved drugs may be suitable for repurposing as prophylactics, or for use in combination with vaccine therapy, to ward off COVID-19.

Tumor Heterogeneity content piece image

Tumor Heterogeneity

Cancer is an extremely complex group of diseases. As it progresses, tumors can evolve to comprise varied cell types with distinct morphological and genetic features. This diversity – or heterogeneity – is reflected at many levels. In this infographic, we explore the mechanisms causing intratumor heterogeneity and the clinical implications of cancer heterogeneity.

Stay Up-to-Date With COVID-19 Drug Development content piece image

Stay Up-to-Date With COVID-19 Drug Development

Researchers are working tirelessly to design new drugs and repurpose existing drugs against the novel coronavirus SARS-CoV-2.

Stay Up-to-Date With COVID-19 Vaccine Development content piece image

Stay Up-to-Date With COVID-19 Vaccine Development

Technology Networks is committed to keeping you updated with the latest research in this space. Here, you'll find a curation of our latest COVID-19 vaccine-related content.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter